Hussein Abdelaziz M, Malek Hala Abdel, Saad Mohamed-Ahdy
a Medical Physiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
b Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Can J Physiol Pharmacol. 2016 Aug;94(8):829-37. doi: 10.1139/cjpp-2015-0364. Epub 2016 Feb 12.
The present study investigated the possible renoprotective effect of direct renin inhibitor (aliskiren) on renal dysfunctions, as well as its underlying mechanisms in rat model of adenine-induced tubulointerstitial nephropathy. Forty male Sprague-Dawley rats were randomized into 4 groups; normal group, aliskiren group (normal rats received 10 mg/kg aliskiren), adenine group (animals received high-adenine diet for 4 weeks and saline for 12 weeks), and adenine + aliskiren group (animals received adenine for 4 weeks and aliskiren 10 mg/kg for 12 weeks). It was found that adenine caused significant decrease in body mass, Hb, HR, serum Ca(2+), eNOS and nrf2 expression, GSH, and catalase in kidney tissues with significant increase in arterial blood pressure (ABP), serum creatinine, BUN, plasma renin activity (PRA), K(+) and P, urinary albumin excretion (UAE), caspase-3, and MDA (lipid peroxidation marker) in kidney tissues compared to normal group (p < 0.05). Administration of aliskiren caused significant improvement in all studied parameters compared to adenine group (p < 0.05). We concluded that aliskiren has renoprotective effect against adenine-induced nephropathy. This might be due to inhibition of PRA, attenuation of oxidative stress, activation of Nrf2 and eNOS genes, and suppression of caspase-3.
本研究探讨了直接肾素抑制剂(阿利吉仑)对肾功能障碍的潜在肾保护作用及其在腺嘌呤诱导的肾小管间质性肾病大鼠模型中的潜在机制。40只雄性Sprague-Dawley大鼠被随机分为4组:正常组、阿利吉仑组(正常大鼠接受10mg/kg阿利吉仑)、腺嘌呤组(动物接受高腺嘌呤饮食4周,生理盐水12周)和腺嘌呤+阿利吉仑组(动物接受腺嘌呤4周,阿利吉仑10mg/kg 12周)。结果发现,与正常组相比,腺嘌呤导致体重、血红蛋白、心率、血清钙(2+)、内皮型一氧化氮合酶和核因子E2相关因子2表达、谷胱甘肽和肾脏组织中过氧化氢酶显著降低,动脉血压(ABP)、血清肌酐、尿素氮、血浆肾素活性(PRA)、钾(+)和磷、尿白蛋白排泄(UAE)、半胱天冬酶-3和丙二醛(脂质过氧化标志物)在肾脏组织中显著升高(p<0.05)。与腺嘌呤组相比,给予阿利吉仑后所有研究参数均有显著改善(p<0.05)。我们得出结论,阿利吉仑对腺嘌呤诱导的肾病具有肾保护作用。这可能是由于抑制PRA、减轻氧化应激、激活Nrf2和eNOS基因以及抑制半胱天冬酶-3。